Result of Annual General Meeting

Nuformix PLC

24 August 2023

 

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,  announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. 

The results of the proxies appointing the Chair of the meeting are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To re-appoint Daniel Gooding as a director	Ordinary	94,720,614	99.67	312,357	0.33%	95,032,971
2	To re-appoint Julian Gilbert as a director	Ordinary	94,720,614	99.67	312,357	0.33%	95,032,971
3	To re-appoint s Madeleine Kennedy as a director	Ordinary	92,448,034	99.66	312,357	0.34%	92,760,391
4	To authorise the Directors to allot shares.	Ordinary	92,082,014	96.19	3,652,015	3.81%	95,734,029
5	To authorise the Directors to disapply pre-emption rights.	Special	92,082,014	98.52	1,379,435	1.48%	93,461,449
6	To authorise the Company to purchase its own shares.	Special	92,306,372	96.32	3,527,841	3.68%	95,834,213
7	To authorise calling of a general meeting on 14 clear days' notice.	Special	93,093,402	97.14	2,740,811	2.86%	95,834,213

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 744,309,368 ordinary shares of £0.001 each.

Enquiries:

Nuformix plc
Dr Daniel Gooding, Executive Director Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.

 

END